Oncology Stakeholders

Depth in understanding of the oncology field is critical for any reliable oncology market research provider.  Providing key insights and recommendations requires a firm grasp of products as well as treatment paradigms, as well as flexibility and innovation in research design – given that "cookie cutter" approaches are seldom possible in oncology, given all the unique circumstances that oncology involves.  HRA prides itself on bringing together oncology expertise with a nimble approach to research design.  The breadth of our custom oncology research is far-reaching, and includes ATUs, segmentation studies, patient demand/patient shares, TPP, SFE/message recall, and other areas.  Members of our team showcase expertise across a variety of cancers/tumor types, including bladder, breast, colorectal, melanoma, NSCLC, ovarian, prostate, renal cell carcinoma, soft tissue sarcoma, NHL, AML, CML, and CLL.  In addition, HRA maintains a pulse on key market issues and stakeholders impacting the oncology space via its strategic syndicated research offerings.  HRA’s study on The Evolving Influence of Oncology Nurse Navigators, for example, provides our clients with perspective on this important stakeholder unavailable anywhere else.  Our Prostate Cancer: Leveraging the Power of the Patient study, explores key decision-points and influencers across the decision-making continuum.